Table of Contents
Ulcers
Volume 2011, Article ID 391787, 5 pages
http://dx.doi.org/10.1155/2011/391787
Review Article

Cytokine Networks in Ulcerative Colitis

Department of Clinical Medicine, Gastroenterology Unit, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy

Received 15 September 2010; Accepted 27 December 2010

Academic Editor: Hiromi Sanada

Copyright © 2011 Giulia Roda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. R. Targan and L. C. Karp, “Defects in mucosal immunity leading to ulcerative colitis,” Immunological Reviews, vol. 206, pp. 296–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. D. K. Podolsky, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 325, pp. 928–937, 1991. View at Google Scholar
  3. S. Targan and F. Shanahan, Inflammatory Bowel Disease: From Bench to Bedside, Williams & Wilkins, Baltimore, Md, USA, 1st edition, 1994.
  4. M. Parkes, M. M. Barmada, J. Satsangi, D. E. Weeks, D. P. Jewell, and R. H. Duerr, “The IBD2 locus shows linkage heterogeneity between ulcerative colitis and Crohn disease,” American Journal of Human Genetics, vol. 67, no. 6, pp. 1605–1610, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Toyoda, S. J. Wang, H. Y. Yang et al., “Distinct associations of HLA class II genes with inflammatory bowel disease,” Gastroenterology, vol. 104, no. 3, pp. 741–748, 1993. View at Google Scholar · View at Scopus
  6. J. Hampe, S. Schreiber, S. H. Shaw et al., “A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort,” American Journal of Human Genetics, vol. 64, no. 3, pp. 808–816, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Ahmad, J. Satsangi, D. Mcgovern, M. Bunce, and D. P. Jewell, “Review article: the genetics of inflammatory bowel disease,” Alimentary Pharmacology and Therapeutics, vol. 15, no. 6, pp. 731–748, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Roussomoustakaki, J. Satsangi, K. Welsh et al., “Genetic markers may predict disease behavior in patients with ulcerative colitis,” Gastroenterology, vol. 112, no. 6, pp. 1845–1853, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Satsangi, K. I. Welsh, M. Bunce et al., “Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease,” Lancet, vol. 347, no. 9010, pp. 1212–1217, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Mayer, “Evolving paradigms in the pathogenesis of IBD,” Journal of Gastroenterology, vol. 45, no. 1, pp. 9–16, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Sanchez-Muñoz, A. Dominguez-Lopez, and J. K. Yamamoto-Furusho, “Role of cytokines in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 27, pp. 4280–4288, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Bouma and W. Strober, “The immunological and genetic basis of inflammatory bowel disease,” Nature Reviews Immunology, vol. 3, no. 7, pp. 521–533, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Baumann and J. Gauldie, “The acute phase response,” Immunology Today, vol. 15, no. 2, pp. 74–80, 1994. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Begue, H. Wajant, J. C. Bambou et al., “Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions,” Gastroenterology, vol. 130, no. 7, pp. 1962–1974, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Bosani, S. Ardizzone, and G. B. Porro, “Biologic targeting in the treatment of inflammatory bowel diseases,” Biologics, vol. 3, pp. 77–97, 2009. View at Google Scholar · View at Scopus
  16. J. M. Reimund, C. Wittersheim, S. Dumont et al., “Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease,” Journal of Clinical Immunology, vol. 16, no. 3, pp. 144–150, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Andoh, Y. Yagi, M. Shioya, A. Nishida, T. Tsujikawa, and Y. Fujiyama, “Mucosal cytokine network in inflammatory bowel disease,” World Journal of Gastroenterology, vol. 14, no. 33, pp. 5154–5161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Griga, U. Hebler, E. Voigt, A. Tromm, and B. May, “Interleukin-4 inhibits the increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease,” Hepato-Gastroenterology, vol. 47, no. 36, pp. 1604–1607, 2000. View at Google Scholar · View at Scopus
  19. S. Kanazawa, T. Tsunoda, E. Onuma, T. Majima, M. Kagiyama, and K. Kikuchi, “VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation,” American Journal of Gastroenterology, vol. 96, no. 3, pp. 822–828, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. I. C. Lawrance, L. Maxwell, and W. Doe, “Inflammation location, but not type, determines the increase in TGF-β1 and IGF-1 expression and collagen deposition in IBD intestine,” Inflammatory Bowel Diseases, vol. 7, no. 1, pp. 16–26, 2001. View at Google Scholar · View at Scopus
  21. B. Del Zotto, G. Mumolo, A. M. Pronio, C. Montesani, R. Tersigni, and M. Boirivant, “TGF-β1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis,” Clinical and Experimental Immunology, vol. 134, no. 1, pp. 120–126, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. G. Rogler and T. Andus, “Cytokines in inflammatory bowel disease,” World Journal of Surgery, vol. 22, no. 4, pp. 382–389, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Reimund, C. Wittersheim, S. Dumont et al., “Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease,” Journal of Clinical Immunology, vol. 16, no. 3, pp. 144–150, 1996. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Bosani, S. Ardizzone, and G. B. Porro, “Biologic targeting in the treatment of inflammatory bowel diseases,” Biologics, vol. 3, pp. 77–97, 2009. View at Google Scholar · View at Scopus
  25. G. Rogler and T. Andus, “Cytokines in inflammatory bowel disease,” World Journal of Surgery, vol. 22, no. 4, pp. 382–389, 1998. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Kuhn, J. Lohler, D. Rennick, K. Rajewsky, and W. Muller, “Interleukin-10-deficient mice develop chronic enterocolitis,” Cell, vol. 75, no. 2, pp. 263–274, 1993. View at Publisher · View at Google Scholar · View at Scopus
  27. D. M. Rennick and M. M. Fort, “Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation,” American Journal of Physiology, vol. 278, no. 6, pp. G829–G833, 2000. View at Google Scholar · View at Scopus
  28. S. Schreiber, T. Heinig, H. G. Thiele, and A. Raedler, “Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease,” Gastroenterology, vol. 108, no. 5, pp. 1434–1444, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Melgar, M. M. W. Yeung, A. Bas et al., “Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis,” Clinical and Experimental Immunology, vol. 134, no. 1, pp. 127–137, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Szkaradkiewicz, R. Marciniak, I. Chudzicka-Strugała et al., “Proinflammatory cytokines and IL-10 in inflammatory bowel disease and colorectal cancer patients,” Archivum Immunologiae et Therapiae Experimentalis, vol. 57, no. 4, pp. 291–294, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Heller, P. Florian, C. Bojarski et al., “Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution,” Gastroenterology, vol. 129, no. 2, pp. 550–564, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. B. E. Sands, W. J. Tremaine, W. J. Sandborn et al., “Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study,” Inflammatory Bowel Diseases, vol. 7, no. 2, pp. 83–88, 2001. View at Google Scholar
  33. T. Ochsenkühn, M. Sackmann, and B. Göke, “Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 11, pp. 1167–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Yamamoto, K. Yoshizaki, T. Kishimoto, and H. Ito, “IL-6 is required for the development of Th1 cell-mediated murine colitis,” Journal of Immunology, vol. 164, no. 9, pp. 4878–4882, 2000. View at Google Scholar · View at Scopus
  35. R. Carey, I. Jurickova, E. Ballard et al., “Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 14, no. 4, pp. 446–457, 2008. View at Publisher · View at Google Scholar · View at Scopus